Salarius Pharmaceuticals Inc (SLRX) FinancialsSLRXSalarius Pharmaceuticals Inc

Decoy Therapeutics Inc (SLRX) generates its revenue primarily from Consumer Operations, which accounts for 100.0% of total sales, equivalent to $164.71K. Understanding this concentration is critical for investors evaluating how SLRX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Decoy Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -139.55%, provide a clear picture of how effectively SLRX converts its operational activities into shareholder value.

In the context of the broader market, SLRX competes directly with industry leaders such as AQB and REVB. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SLRX's gross margin of N/A stands against AQB's N/A and REVB's N/A. Such benchmarking helps identify whether Decoy Therapeutics Inc is trading at a premium or discount relative to its financial performance.